◎ Sugi Atlas

Atlas / Drug / Progesterone

Progesterone

drug
On this page

Also known as CrinoneCyclogestEndometrinLutigestMilprosaNSC-64377NSC-9704ProchieveProgesta-careProgestasertProgesteronaProgesterone component of bijuvamicronizedProgesteronumPrometriumProgestinRegumateSerenity for womenSyngestrone

Summary

Progesterone (CHEMBL103) is an approved small-molecule contraceptive drug (ATC G03DA04) targeting CATSPER1, CATSPER2, and CATSPER3; indicated across 47 conditions including amenorrhea and atypical endometrial hyperplasia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: G03DA04
  • Targets: 7 (CATSPER1, CATSPER2, CATSPER3…)
  • Indications: 47 conditions
  • Clinical trials: 315
  • Chemistry: 314.5 Da · C21H30O2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL103
NameProgesterone
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5994
ChEBICHEBI:17026
ATCG03DA04
Molecular formulaC21H30O2
Molecular weight314.5
InChIKeyRJKFOVLPORLFTN-LEKSSAKUSA-N

SMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C

IUPAC name: (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

ChEBI definition: A C21-steroid hormone in which a pregnane skeleton carries oxo substituents at positions 3 and 20 and is unsaturated at C(4)-C(5). As a hormone, it is involved in the female menstrual cycle, pregnancy and embryogenesis of humans and other species.

Pharmacological roles (ChEBI): contraceptive drug, progestin, progesterone receptor agonist.

Other ChEBI roles (chemical / environmental): human metabolite, mouse metabolite.

Also known as: Crinone, Cyclogest, Endometrin, Lutigest, Milprosa, NSC-64377, NSC-9704, Prochieve, Progesta-care, Progestasert, Progesterona, Progesterone

Patent coverage: 52,333 distinct patent families (162,141 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
CATSPER1CatSper1Full agonist8.111.8%Q8NEC5
CATSPER2CatSper2Full agonist8.110.2%Q96P56
CATSPER3CatSper3Full agonist8.110.6%Q86XQ3
CATSPER4CatSper4Full agonist8.110.2%Q7RTX7
Glycine Receptor (All subtypes)Inhibition
TRPC5TRPC5Inhibition5.30%Q9UL62
NR3C2Mineralocorticoid receptorAntagonist110%P08235
PGRProgesterone receptorAgonist8.460.1%P06401

Broader ChEMBL bioactivity targets: 53 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, Ferritin light chain, Thrombopoietin, Ras-related protein Rab-9A, Peripheral myelin protein 22, Solute carrier family 22 member 2.

Bioactivity

ChEMBL activities: 115 potent at pChembl ≥ 5 of 158 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PGR10EC500.1nMCHEMBL_ACT_3224266
PGR9.74EC500.18nMCHEMBL_ACT_24514867
PGR9.7IC500.2nMCHEMBL_ACT_5221854
NR3C29.41Kd0.39nMCHEMBL_ACT_1082433
PGR9.3EC500.5nMCHEMBL_ACT_2448979
PGR9.05EC500.9nMCHEMBL_ACT_2369822
PGR9.05EC500.9nMCHEMBL_ACT_269054
PGR9.04EC500.92nMCHEMBL_ACT_269056
PGR9.04EC500.92nMCHEMBL_ACT_416554
PGR8.92AC501.2nMCHEMBL_ACT_25223579
PGR8.82EC501.5nMCHEMBL_ACT_860293
PGR8.74EC501.8nMCHEMBL_ACT_263045
PGR8.74EC501.8nMCHEMBL_ACT_296090
PGR8.74EC501.8nMCHEMBL_ACT_57303
PGR8.7EC502nMCHEMBL_ACT_15068947
PGR8.66EC502.2nMCHEMBL_ACT_2448994
PGR8.54EC502.9nMCHEMBL_ACT_1203354
PGR8.54EC502.9nMCHEMBL_ACT_263040
PGR8.54EC502.9nMCHEMBL_ACT_296085
PGR8.54EC502.9nMCHEMBL_ACT_315394
PGR8.54EC502.9nMCHEMBL_ACT_57301
PGR8.54EC502.9nMCHEMBL_ACT_595052
PGR8.54EC502.89nMCHEMBL_ACT_696861
PGR8.54EC502.9nMCHEMBL_ACT_860310
PGR8.48AC503.3nMCHEMBL_ACT_25204915
PGR8.47Ki3.4nMCHEMBL_ACT_2449035
PGR8.46Ki3.5nMCHEMBL_ACT_1203357
PGR8.46Ki3.47nMCHEMBL_ACT_1734227
PGR8.46Ki3.5nMCHEMBL_ACT_263041
PGR8.46Ki3.5nMCHEMBL_ACT_296088

Target pathways

Aggregated over 7 target gene(s): CATSPER1, CATSPER2, CATSPER3, CATSPER4, TRPC5, NR3C2, PGR.

Top Reactome pathways

16 total, by targets touching each:

PathwayTargetsGenes
Sperm Motility And Taxes4CATSPER1, CATSPER2, CATSPER3, CATSPER4
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand2NR3C2, PGR
Nuclear Receptor transcription pathway2NR3C2, PGR
SUMOylation of intracellular receptors2NR3C2, PGR
Nuclear signaling by ERBB41PGR
Cellular responses to stress1NR3C2
SUMOylation1NR3C2
SUMO E3 ligases SUMOylate target proteins1NR3C2
TRP channels1TRPC5
Metabolism of proteins1NR3C2
Role of second messengers in netrin-1 signaling1TRPC5
Post-translational protein modification1NR3C2
Cellular responses to stimuli1NR3C2
Estrogen-dependent gene expression1PGR
Developmental Lineage of Mammary Gland Luminal Epithelial Cells1PGR
Developmental Lineage of Mammary Gland Alveolar Cells1PGR

Dominant GO biological processes

GO termTargets
calcium ion transport5
monoatomic ion transport5
monoatomic ion transmembrane transport5
transmembrane transport5
calcium ion transmembrane transport5
spermatogenesis4
cell differentiation4
flagellated sperm motility4
sperm capacitation3
monoatomic cation transmembrane transport2
sodium ion transport2
establishment of localization in cell2
regulation of transcription by RNA polymerase II2
signal transduction2
nuclear receptor-mediated steroid hormone signaling pathway2

Indications & clinical

Indications

47 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
amenorrhea4MONDO:0001836EFO:0010269
atypical endometrial hyperplasia4MONDO:0006096EFO:1000098
infertility disorder3MONDO:0005047EFO:0000545
breast neoplasm3MONDO:0021100EFO:0003869
epilepsy3MONDO:0005027EFO:0000474
uterine corpus leiomyoma3MONDO:0007886EFO:0000731
female infertility3MONDO:0021124EFO:0008560
diabetes mellitus3MONDO:0005015EFO:0000400
hypertensive disorder3MONDO:0005044EFO:0000537
osteoporosis3MONDO:0005298EFO:0003882
intermediate coronary syndrome3MONDO:0006805EFO:1000985
myocardial ischemia3MONDO:0024644EFO:1001375
thrombotic disease3MONDO:0000831MONDO:0000831
brain injury3MONDO:0043510MONDO:0043510
coronary artery disorder3MONDO:0005010EFO:0001645
ovarian neoplasm3MONDO:0021068EFO:0003893
Alzheimer disease3MONDO:0004975MONDO:0004975
ovarian hyperstimulation syndrome3MONDO:0011972MONDO:0011972
breast carcinoma3MONDO:0004989EFO:0000305
cardiovascular disorder3MONDO:0004995EFO:0000319
bone disorder3MONDO:0005381EFO:0004260
cocaine dependence2MONDO:0005186EFO:0002610
nicotine dependence2MONDO:0008575EFO:0003768
preeclampsia2MONDO:0005081EFO:0000668
HIV infectious disease2MONDO:0005109EFO:0000180
polycystic ovary syndrome2MONDO:0008487EFO:0000660
vulvar lichen sclerosus2MONDO:0006491EFO:1000623
postural orthostatic tachycardia syndrome2MONDO:0011479EFO:1000645
cannabis dependence2MONDO:0005689EFO:0007191
placenta praevia2MONDO:0005918EFO:0007442
postpartum depression2MONDO:0005929EFO:0007453
bulimia nervosa2MONDO:0005452EFO:0005204
endometrium neoplasm2MONDO:0021251MONDO:0011962
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
anorexia nervosa2MONDO:0005351MONDO:0005351
dysplasia of cervix2MONDO:0006736MONDO:0022394
depressive disorder2MONDO:0002050MONDO:0002050
methamphetamine dependence0MONDO:0005419EFO:0004701
gliosarcoma0MONDO:0016681EFO:1001465

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 315.

Phase distribution

PhaseTrials
Not specified97
PHASE480
PHASE353
PHASE244
PHASE116
PHASE2/PHASE311
EARLY_PHASE19
PHASE1/PHASE25

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05282277PHASE4RECRUITINGExamining the Effects of Estradiol on Neural and Molecular Response to Reward
NCT05704036PHASE4RECRUITINGEstrogen Supplementation and Bone Health in Women With CF
NCT06396390PHASE4NOT_YET_RECRUITINGComparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes
NCT06610305PHASE4RECRUITINGOvarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
NCT06856174PHASE4RECRUITINGMenopausal HT for Women Living With HIV (HoT)
NCT06875752PHASE4RECRUITINGIs There a Need for Luteal Support in Modified Natural Cycle Frozen Embryo Transfer Cycles
NCT06896617PHASE4RECRUITINGImpact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)
NCT07448597PHASE4NOT_YET_RECRUITINGProgesterone Preeclampsia
NCT07508657PHASE4NOT_YET_RECRUITINGProgesterone Supplementation After Letrozole-stimulated Insemination
NCT00154180PHASE4UNKNOWNKronos Early Estrogen Prevention Study (KEEPS)
NCT00530582PHASE4COMPLETEDProgesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women
NCT00646802PHASE4COMPLETEDVaginal PROgesterone as Maintenance Treatment After an epISode of prEterm Labor (PROMISE Study)
NCT00656201PHASE4COMPLETEDComparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)
NCT00708539PHASE4UNKNOWNA Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.
NCT00732693PHASE4COMPLETEDEvaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00755963PHASE4COMPLETEDEffects of Hormone Replacement Therapy on the Serotonergic System and Mood in Postmenopausal Women
NCT00954811PHASE4UNKNOWNLuteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)
NCT01031017PHASE4COMPLETEDProphylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies
NCT01123538PHASE4UNKNOWNProgestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile
NCT01225835PHASE4COMPLETEDProgesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)
NCT01237535PHASE4UNKNOWNLuteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates
NCT01286246PHASE4TERMINATEDRandomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor
NCT01465373PHASE4COMPLETEDVaginal Progesterone Versus Progesterone in Oil in Donor Egg Recipient In Vitro Fertilization Cycles Utilizing Vitrified Donor Eggs
NCT01670929PHASE4COMPLETEDPr-conceptional Progesterone for Unexplained Recurrent Miscarriage
NCT01809639PHASE4COMPLETEDDoes Oral Micronized Progesterone Shorten Time of Symptoms From Concussion
NCT01888744PHASE4COMPLETEDPreimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist
NCT01927029PHASE4UNKNOWNPreterm Delivery Prevention in Twins With Progesterone
NCT01940653PHASE4COMPLETEDOptimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone
NCT01954966PHASE4COMPLETEDProgesterone and Brain Imaging Study
NCT01966575PHASE4WITHDRAWNEffect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate
NCT01980680PHASE4COMPLETEDThe Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients
NCT02032797PHASE4COMPLETEDOptimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.
NCT02255175PHASE4COMPLETEDPerimenopausal Effects of Estradiol on Reward Responsiveness
NCT02316626PHASE4COMPLETEDSubcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support
NCT02338830PHASE4COMPLETEDVaginal Progesterone for Prevention of Preterm Labor in Asymptomatic Twin Pregnancies With Sonographic Short Cervix
NCT02363127PHASE4COMPLETEDSubcutaneous Progesterone Versus Vaginal Progesterone for Endometrial Preparation in Fresh Donated Oocytes Recipients
NCT02372942PHASE4UNKNOWNLactoferrin or Progesterone for Prevention of Preterm Delivery
NCT02511574PHASE4COMPLETEDComparison Between Natural Progesterone and Vaginal Pessary for the Prevention of Spontaneous Preterm Birth
NCT02513940PHASE4COMPLETEDInfluence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT02567552PHASE4COMPLETEDClinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

301 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
dinoprostoneChEMBL + PubChemPhase 4 (approved)CATSPER1, CATSPER4, PGR
EnzalutamideChEMBL + PubChemPhase 4 (approved)NR3C2, PGR
EPLERENONEChEMBL + PubChemPhase 4 (approved)NR3C2, PGR
FludrocortisoneChEMBL + PubChemPhase 4 (approved)NR3C2, PGR
BUDESONIDEChEMBLPhase 4 (approved)NR3C2, PGR
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C2, PGR
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C2, PGR
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C2, PGR
HYDROCORTISONEChEMBLPhase 4 (approved)NR3C2, PGR
HYDROCORTISONE BUTYRATEChEMBLPhase 4 (approved)NR3C2, PGR
MEDROXYPROGESTERONEChEMBLPhase 4 (approved)NR3C2, PGR
MIFEPRISTONEChEMBLPhase 4 (approved)NR3C2, PGR
PREDNISOLONEChEMBLPhase 4 (approved)NR3C2, PGR
SPIRONOLACTONEChEMBLPhase 4 (approved)NR3C2, PGR
QUERCETINChEMBL + PubChemPhase 3 (approved)PGR, TRPC5
ASOPRISNILChEMBLPhase 3NR3C2, PGR
METRIBOLONEChEMBLPhase 2NR3C2, PGR
ONAPRISTONEChEMBLPhase 2NR3C2, PGR
STANOLONEChEMBLPhase 2NR3C2, PGR
TUROFEXORATE ISOPROPYLChEMBLPhase 2NR3C2, PGR
AlprostadilPubChemApprovedCATSPER1, CATSPER4
FIDAXOMICINChEMBL + PubChemPhase 4 (approved)PGR
FULVESTRANTChEMBL + PubChemPhase 4 (approved)PGR
GENTIAN VIOLETChEMBL + PubChemPhase 4 (approved)PGR
ABIRATERONEChEMBLPhase 4 (approved)PGR
ACETYLCHOLINEChEMBLPhase 4 (approved)PGR
ADAPALENEChEMBLPhase 4 (approved)PGR
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)PGR
ALECTINIBChEMBLPhase 4 (approved)PGR
AMCINONIDEChEMBLPhase 4 (approved)PGR
APOMORPHINEChEMBLPhase 4 (approved)PGR
ARFORMOTEROLChEMBLPhase 4 (approved)PGR
ARIPIPRAZOLEChEMBLPhase 4 (approved)PGR
AZATHIOPRINEChEMBLPhase 4 (approved)PGR
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)PGR
BENPERIDOLChEMBLPhase 4 (approved)PGR
BENZBROMARONEChEMBLPhase 4 (approved)PGR
BENZIODARONEChEMBLPhase 4 (approved)PGR
BETAMETHASONEChEMBLPhase 4 (approved)PGR
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)PGR
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)PGR
BEXAROTENEChEMBLPhase 4 (approved)PGR
BICALUTAMIDEChEMBLPhase 4 (approved)PGR
BIFONAZOLEChEMBLPhase 4 (approved)PGR
BITHIONOLChEMBLPhase 4 (approved)PGR
BOSUTINIBChEMBLPhase 4 (approved)PGR
BUTOCONAZOLEChEMBLPhase 4 (approved)PGR
CABOZANTINIBChEMBLPhase 4 (approved)PGR
CALCIPOTRIENEChEMBLPhase 4 (approved)PGR
CALCITRIOLChEMBLPhase 4 (approved)PGR
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)PGR
CANRENONEChEMBLPhase 4 (approved)PGR
CARBARILChEMBLPhase 4 (approved)PGR
CASPOFUNGINChEMBLPhase 4 (approved)PGR
CEFAMANDOLEChEMBLPhase 4 (approved)PGR
CEFMENOXIMEChEMBLPhase 4 (approved)PGR
CEFTAZIDIMEChEMBLPhase 4 (approved)PGR
CEFTIZOXIMEChEMBLPhase 4 (approved)PGR
CEFTRIAXONEChEMBLPhase 4 (approved)PGR
CEFUROXIMEChEMBLPhase 4 (approved)PGR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot